In the News
Reuters: Novartis taps into gene editing for next generation drugs
Novartis is diving deeper into the world of gene-based medicine by signing deals with two U.S. biotech companies, giving it access to a powerful new genome editing technology.
PharmaTimes: Novartis in genome editing pacts with Intellia, Caribou
Novartis is buying into CRISPR gene editing technology via two separate deals with Intellia Therapeutics and Caribou Biosciences.
Genetic Engineering News: Novartis Launches CRISPR Collaborations with Intellia, Caribou
Novartis said today it is launching collaborations with a pair of partners that will enable it to use CRISPR genome editing technology to discover and develop new medicines. The value of both collaborations was undisclosed.
UC Berkeley News Center: Jennifer Doudna elected to the National Academy of Inventors
Three UC Berkeley, faculty members whose innovations have launched new startups and whole new areas of research have been named fellows of the National Academy of Inventors.
Xconomy: With Atlas Cash and Berkeley Tools, Intellia Joins the CRISPR Fray
Add another entrant to the race toward what might be called Gene Therapy 2.0. Atlas Venture and the research arm of the drug giant Novartis (NYSE: NVS) have put $15 million into the Series A round for Intellia Therapeutics, which is emerging today from stealth after two years of incubation.